80 related articles for article (PubMed ID: 25629154)
1. Safety referral procedures clarified.
Prescrire Int; 2014 Dec; 23(155):304-5. PubMed ID: 25629154
[TBL] [Abstract][Full Text] [Related]
2. European pharmacovigilance: increasingly outsourced to drug companies.
Prescrire Int; 2014 Dec; 23(155):302-3, 305-7. PubMed ID: 25629153
[TBL] [Abstract][Full Text] [Related]
3. Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes.
Laroche ML; Batz A; Géniaux H; Féchant C; Merle L; Maison P
Therapie; 2016 Apr; 71(2):161-9. PubMed ID: 27080834
[TBL] [Abstract][Full Text] [Related]
4. A description of medicines-related safety issues evaluated through a referral procedure at the EU level after 2012.
Farcas A; Balcescu T; Anghel L; Bucsa C; Mogoșan C
Expert Opin Drug Saf; 2020 Jun; 19(6):755-762. PubMed ID: 32186202
[TBL] [Abstract][Full Text] [Related]
5. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
[TBL] [Abstract][Full Text] [Related]
6. A critical assessment of the European Commission's proposals for the risk assessment and registration of chemical substances in the European Union.
Combes R; Dandrea J; Balls M
Altern Lab Anim; 2006 Mar; 34 Suppl 1():29-40. PubMed ID: 16555958
[TBL] [Abstract][Full Text] [Related]
7. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
Tomić S; Sucić AF; Martinac AI
Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
[TBL] [Abstract][Full Text] [Related]
8. Pharmacovigilance and biosimilars: considerations, needs and challenges.
Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
[TBL] [Abstract][Full Text] [Related]
9. ICRP publication 109. Application of the Commission's Recommendations for the protection of people in emergency exposure situations.
Clarke R; Valentin J;
Ann ICRP; 2009; 39(1):1-110. PubMed ID: 19853177
[TBL] [Abstract][Full Text] [Related]
10. Duration of Effectiveness Evaluation of Additional Risk Minimisation Measures for Centrally Authorised Medicinal Products in the EU Between 2012 and 2021.
Essink SCM; Zomerdijk IM; Straus SMJM; Gardarsdottir H; De Bruin ML
Drug Saf; 2023 Oct; 46(10):1007-1020. PubMed ID: 37658281
[TBL] [Abstract][Full Text] [Related]
11. Direct access and patient/client self-referral to physiotherapy: a review of contemporary practice within the European Union.
Bury TJ; Stokes EK
Physiotherapy; 2013 Dec; 99(4):285-91. PubMed ID: 23537881
[TBL] [Abstract][Full Text] [Related]
12. European regulations relevant to the marketing and use of fish vaccines.
Lee A
Dev Biol Stand; 1997; 90():341-6. PubMed ID: 9270862
[TBL] [Abstract][Full Text] [Related]
13. How to improve the clinical development paradigm and its division into phases I, II and III.
Bamberger M; Moore N; Lechat P;
Therapie; 2011; 66(4):331-4, 327-30. PubMed ID: 21851796
[TBL] [Abstract][Full Text] [Related]
14. European regulations on nutraceuticals, dietary supplements and functional foods: a framework based on safety.
Coppens P; da Silva MF; Pettman S
Toxicology; 2006 Apr; 221(1):59-74. PubMed ID: 16469424
[TBL] [Abstract][Full Text] [Related]
15. The prospects for using (Q)SARs in a changing political environment--high expectations and a key role for the European Commission's joint research centre.
Worth AP; Van Leeuwen CJ; Hartung T
SAR QSAR Environ Res; 2004; 15(5-6):331-43. PubMed ID: 15669693
[TBL] [Abstract][Full Text] [Related]
16. Are occupational exposure limits becoming more alike within the European Union?
Schenk L; Hansson SO; Rudén C; Gilek M
J Appl Toxicol; 2008 Oct; 28(7):858-66. PubMed ID: 18381691
[TBL] [Abstract][Full Text] [Related]
17. Triage of referrals to an outpatient rheumatology clinic: analysis of referral information and triage.
Graydon SL; Thompson AE
J Rheumatol; 2008 Jul; 35(7):1378-83. PubMed ID: 18484689
[TBL] [Abstract][Full Text] [Related]
18. [Europe and medicines: role of the EMEA].
Sauer F
Ann Pharm Fr; 2000 Jul; 58(4):278-85. PubMed ID: 10915977
[TBL] [Abstract][Full Text] [Related]
19. European Union centralised procedure for marketing authorisation of oncology drugs: an in-depth review of its efficiency.
Netzer T
Eur J Cancer; 2006 Mar; 42(4):446-55. PubMed ID: 16129598
[TBL] [Abstract][Full Text] [Related]
20. Issues in consumer exposure modeling: towards harmonization on a global scale.
Kephalopoulos S; Bruinen de Bruin Y; Arvanitis A; Hakkinen P; Jantunen M
J Expo Sci Environ Epidemiol; 2007 Dec; 17 Suppl 1():S90-100. PubMed ID: 17668010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
